The decision against Syfovre’s approval follows efforts by Apellis to have reviewers reevaluate clinical evidence multiple times and, according to an analyst, will lead to a restructuring of the ...

Shares dropped by as much as one-quarter Thursday after the biotech shared longer-term results for a gene therapy it’s developing for wet AMD.

In a letter to CEO Anne Wojcicki, the directors said they’d resign “rather than have a protracted and distracting difference of view with you” about the company’s future.

U.K.-based biotechnology company F2G has raised $100 million to complete late-stage testing of a new kind of antifungal treatment and bring it back to U.S. regulators’ desks after they rejected it ...